IP Verse

Heterodimeric Bispecific Antibodies - EP2970484

The patent EP2970484 was granted to Amgen on Sep 21, 2022. The application was originally filed on Mar 13, 2014 under application number EP14722862A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2970484

AMGEN
Application Number
EP14722862A
Filing Date
Mar 13, 2014
Status
Patent Maintained As Amended
Aug 19, 2022
Grant Date
Sep 21, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

RICKERFeb 15, 2019WALLINGER RICKER SCHLOTTER TOSTMANNADMISSIBLE

Patent Citations (16) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTEP2050764
INTERNATIONAL-SEARCH-REPORTWO2008024188
INTERNATIONAL-SEARCH-REPORTWO2010037836
INTERNATIONAL-SEARCH-REPORTWO2012025530
INTERNATIONAL-SEARCH-REPORTWO2012118903
INTERNATIONAL-SEARCH-REPORTWO2012135345
OPPOSITIONUS2004033561
OPPOSITIONUS2009060910
OPPOSITIONUS5837242
OPPOSITIONWO0202781
OPPOSITIONWO2007048037
OPPOSITIONWO2008157379
OPPOSITIONWO2012125850
OPPOSITIONWO2013096221
OPPOSITIONWO2014106015
OPPOSITIONWO2014145806

Non-Patent Literature (NPL) Citations (10) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
INTERNATIONAL-SEARCH-REPORT- CHRISTIAN KLEIN ET AL, "Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies", MABS, (20121101), vol. 4, no. 6, doi:10.4161/mabs.21379, ISSN 1942-0862, pages 653 - 663, XP055106060 [Y] 31,32 * the whole document *
OPPOSITION- BARGOU, RC, "Tumor regression in cancer patients by very low doses of a T cell-engaging antibody", Educ. Contin Saude, (20090000), pages 71 - 72, XP055569739-
OPPOSITION- RIDGWAY, JB, "'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization", Protein Eng., (19960700), vol. 9, no. 7, pages 617 - 21, XP002084766-
OPPOSITION- STROHL WR, "Optimization of Fc-mediated effector functions of monoclonal antibodies", Curr Opin Biotechnol, (20091200), vol. 20, no. 6, pages 685 - 691, XP002631328
OPPOSITION- HOLLIGER et al., ""Diabodies": small bivalent and bispecific antibody fragments", Proc. Natl. Acad. Sci. USA, (19930700), vol. 90, pages 6444 - 6448, XP002008022
OPPOSITION- GUNASEKARAN K et al., "Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG (manuscript)", JBC Papers in Press, (20100416), vol. 285, no. 25, pages 1 - 20, XP055569730
OPPOSITION- HEZAREH, M. et al., "Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1", J Virol., (20010000), pages 12161 - 12168, XP002339184
OPPOSITION- BAEUERLE PA, "Bispecific T-cell engaging antibodies for cancer therapy", Cancer Res., (20090615), vol. 69, no. 12, pages 4941 - 4944, XP002665118
OPPOSITION- KONTERMANN RE, "Strategies to extend plasma half-lives of recombinant antibodies", BioDrugs, (20090000), vol. 23, no. 2, pages 93 - 109, XP008124089
OPPOSITION- KONTERMANN RE, "Dual targeting strategies with bispecific antibodies", MAbs, (20120300), vol. 4, no. 2, pages 182 - 197, XP002698995

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents